Skip to main content

Table 1 Summary of input data used in the model

From: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Subgroup Value (lower and upper CI) Reference
Baseline risk of hospitalisation
CHD infants 9.7% (7.4%, 12.0%) Feltes et al. 2003 [5]
CLD infants 12.8% (8.8%, 16.8%) IMPACT, 1998 [6]
Preterm: <29 wGA 10.00% (0.7%, 19.3%) MedImmune/Abbott, Data on File.
Preterm: 29–32 wGA 7.69% (2.86%, 12.5%) MedImmune/Abbott, Data on File.
Preterm: 33–35 wGA 7.69% (2.86%, 12.5%) MedImmune/Abbott, Data on File.
Relative risk reduction of RSV hospitalisation with palivizumab prophylaxis
CHD infants 45.3% (18.1%, 63.4%) Feltes et al. 2003 [5]
CLD infants 38.5% (5.0%, 60.2%) IMPACT, 1998 [6]
Preterm: <29 wGA 80.39% (0.00%, 96.26%) MedImmune/Abbott, Data on File.
Preterm: 29–32 wGA 79.69% (35.38%, 93.62%) MedImmune/Abbott, Data on File.
Preterm: 33–35 wGA 73.16% (54.87%, 93.09%) MedImmune/Abbott, Data on File.
Mortality rates of children hospitalised due to RSV disease
CHD infants 3.72% (1.19%, 6.23%) Wang et al. 2008 [14]
CLD infants 4.00% (3.00%, 5.00%) Wang et al. 2008 [14]
Preterm infants 0.43% (0.23%, 0.63%) Wang et al. 2008 [14]
Life expectancy
CHD infants 76.0 years (75.0††, 78.9††) Office for National Statistics [25]
All other subgroups 79.0 years (77.9††, 82.0††) Office for National Statistics [25]
Risk of RSV-related sequelae
Increase in resource use 2 years Greenough et al. 2001 [24]
Decrease in utility 5 years Greenough et al. 2004 [21]
Drug and administration costs
Palivizumab (50 mg vial) £306.64/pack (£6.13/mg) MIMS [27]
Palivizumab (100 mg vial) £563.64/pack (£5.64/mg) MIMS [27]
Initial administration by hospital nurse £41 (£23, £47) Costs of Health and Social Care 2009–2010 [29]
Subsequent administration by GP practice nurse £31 (£26, £36) Costs of Health and Social Care 2009–2010 [29]
Rate of hospital admissions for RSV (% of patients)
CHD children in general ward 100% Assumption
CHD children in Intensive Care Unit (ICU) 38.14% (28.48%, 47.81%) Feltes CSR [16]
All other infants; General ward 100% Assumption
All other infants; Intensive Care Unit (ICU) 27.45% (18.79%, 47.81%) FDA - Palivizumab Clinical Review [2]
Length of stay of hospital admissions for RSV patients
CHD children in general ward 12.40 (9.30, 18.99§) FDA - Palivizumab Clinical Review [2]
CHD children in Intensive Care Unit (ICU) 15.19 (11.39, 15.50§) FDA - Palivizumab Clinical Review [2]
All other infants; General ward 6.64 (4.98, 8.32§) FDA - Palivizumab Clinical Review [2]
All other infants; Intensive Care Unit (ICU) 7.04 (5.28, 8.80§) FDA - Palivizumab Clinical Review [2]
Cost per day of RSV hospitalisation
General ward £555 (£406*, £1,955*) NHS National Schedule of Reference Costs [28]
Intensive Care Unit (ICU) £2,225 (£311*, £1,954*) NHS National Schedule of Reference Costs [28]
Medical cost of sequelae (recurrent wheeze/asthma)
Annual per patient cost for all other subgroups £14, 015 Greenough et al., 2004 [21]; Costs of Health and Social Care 2009–2010 [29]; NHS National Schedule of Reference Costs [28]
Annual per patient cost for 33–35 wGA £810 (£0, £8,972) Shefali-Petal et al., 2011 [22]
Health state utility values (Utility (SE); (Lower and upper CI)
Non RSV-H patients 0.95 (0.25); (0.03, 1.00‡‡) Greenough et al., 2004 [21]
Patients admitted with RSV-H 0.88 – Modelled as 7.37% (0.94%) reduction; (5.53%, 9.21%§) Greenough et al., 2004 [21]
  1. Abbreviations: CI Confidence interval, CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, GP General practitioner, SE Standard error, RSV-H Respiratory syncytial virus hospitalisation. †Beta distribution; ‡ Gamma distribution; Log-normal distribution. †† The lower and upper confidence intervals are based on the average life expectancy of males and females respectively. § Estimated assuming a confidence interval of ± 25%. * Interquartile range. ‡‡ Plausible range.